Urinary Tract Infection (Paediatrics)

1. Clinical Overview

Summary

Urinary Tract Infection (UTI) is the most common serious bacterial infection in children, accounting for approximately 7 million office visits and 100,000 hospitalizations annually. [1] It ranges from benign lower tract cystitis to life-threatening pyelonephritis with potential for long-term renal damage.

The Stakes: In children less than 2 years, the growing kidney is highly vulnerable to permanent renal scarring from acute pyelonephritis. This inflammatory damage can lead to hypertension, proteinuria, and chronic kidney disease in adult life, with reflux nephropathy being a leading cause of end-stage renal failure in paediatric populations. [1,2]

The Challenge: Diagnosis is notoriously difficult in pre-verbal children. An 8-month-old cannot articulate dysuria or frequency. They present with non-specific fever, irritability, or vomiting—masquerading as viral illness while kidney damage silently progresses. [3]

The Evidence Mandate: Management has evolved significantly. Modern practice emphasizes judicious imaging to minimize radiation exposure, restrictive use of antibiotic prophylaxis (no longer routine), and aggressive treatment of modifiable risk factors—particularly bladder-bowel dysfunction. [4,5]

Clinical Pearls

The "Silent" Pyelonephritis: In infants less than 12 months, fever may be the only manifestation. The classic adult triad of dysuria, frequency, and flank pain is rare below age 5 years. Any unexplained fever in this age group mandates urine sampling. [3,6]

Constipation is King: Up to 80% of recurrent UTIs are driven by functional constipation and bladder-bowel dysfunction. A loaded rectum compresses the bladder anteriorly, causing incomplete emptying, urinary stasis, and recurrent infection. You cannot cure recurrent UTI without addressing bowel function. [7]

Bag vs Catch Paradox: A positive bag urine specimen has poor specificity (high contamination rate) and should never be used to diagnose UTI. However, a negative bag specimen has excellent negative predictive value and can effectively exclude infection. Confirmatory clean-catch or catheter samples are essential for positive results. [8]

The Circumcision Effect: Male circumcision reduces UTI risk by 72-90% in the first year of life, with the protective effect most pronounced in infants with antenatal hydronephrosis or vesicoureteral reflux. [9,10]

---

2. Epidemiology

Overall Prevalence

UTI affects 1 in 10 girls and 1 in 30 boys by age 16 years. [11] Among febrile infants presenting for medical evaluation, the pooled prevalence of UTI is 7.0% (95% CI: 5.5-8.4). [3]

Age-Specific Patterns

Gender Dynamics

Neonatal Period (less than 3 months): Boys experience higher UTI rates than girls, primarily related to higher incidence of congenital anomalies of the kidney and urinary tract (CAKUT) and uncircumcised status. [3]

Beyond 1 year: Female predominance emerges, reflecting shorter urethral length (4 cm vs 20 cm in males) and proximity to perineal/perianal flora.

Racial Differences

White infants have higher baseline UTI prevalence (8.0%, 95% CI: 5.1-11.0) compared to Black infants (4.7%, 95% CI: 2.1-7.3). [3] The mechanism remains unclear but may relate to differences in bacterial adherence factors or host immune responses.

Impact of Circumcision

Meta-analysis data (2023): Among 8,968 children with antenatal hydronephrosis, circumcision reduced UTI incidence from 18.1% to 4.9% (pooled OR 0.28, 95% CI 0.23-0.32). This protective effect was consistent across all causes of hydronephrosis including vesicoureteral reflux, posterior urethral valves, and pelviureteric junction obstruction. [10]

Economic Burden

Community-acquired UTI costs approximately $1.6 billion annually in the United States alone, accounting for healthcare utilization, lost productivity, and long-term sequelae management. [1]

Future Directions

Emerging research areas:

1. Microbiome-based prevention: Probiotics targeting urogenital flora restoration
2. Rapid molecular diagnostics: PCR-based pathogen identification (reduces time to targeted therapy from 48h to 2h)
3. Biomarker-guided imaging: Using PCT/CRP algorithms to risk-stratify children for DMSA scanning
4. Novel antimicrobials: Development of agents against MDR organisms (e.g., fosfomycin, new beta-lactamase inhibitors)

---

3. Microbiology & Pathophysiology

Causative Organisms

Escherichia coli dominates, accounting for 80-90% of community-acquired UTIs in children. [12,13] Its uropathogenic strains possess specific virulence factors:

• P fimbriae: Mediate bacterial adherence to uroepithelial cells
• Type 1 fimbriae: Enable bladder colonization
• Alpha-hemolysin: Causes direct cellular damage
• Capsular polysaccharide: Evades host immune response

Other Pathogens (10-20%):

• Klebsiella pneumoniae: 5-10%, more common in hospitalized/catheterized children
• Proteus mirabilis: 3-5%, associated with urease production and struvite stones
• Enterococcus species: 2-5%, often nosocomial
• Pseudomonas aeruginosa: less than 2%, suggests structural abnormality or recent instrumentation
• Staphylococcus saprophyticus: Rare in children (more common in adolescent females)

Atypical Organisms (Proteus, Pseudomonas, Klebsiella, Pseudomonas): Their presence defines "atypical UTI" and mandates imaging investigation for structural anomalies, stones, or obstruction. [4,14]

Pathophysiological Sequence

Step 1: Perineal Colonization

Enteric bacteria (predominantly E. coli) from the gastrointestinal tract colonize the perineum and periurethral area. Poor hygiene, constipation (fecal loading), and tight clothing increase bacterial density.

Step 2: Urethral Ascension

Bacteria ascend the urethra into the bladder. Risk factors include:

• Voiding dysfunction: Infrequent voiding, incomplete bladder emptying
• Bladder-bowel dysfunction: Constipation causes mechanical compression and detrusor instability
• Anatomical factors: Short female urethra, uncircumcised male prepuce (bacterial reservoir)

Step 3: Bladder Infection (Cystitis)

Bacteria multiply in bladder urine. Host defense mechanisms include:

• Tamm-Horsfall protein: Binds bacteria to prevent mucosal attachment
• Urine flow: Mechanical washout
• Low pH and high osmolality: Inhibit bacterial growth
• Bladder epithelial immunity: Local IgA production

When these defenses are overwhelmed, cystitis develops—characterized by dysuria, frequency, and suprapubic pain (in older children).

Step 4: Upper Tract Invasion (Pyelonephritis)

Two mechanisms:

A. Direct Ureteric Ascension: Bacteria travel up ureters to kidneys via peristaltic reflux or turbulent flow.

B. Vesicoureteric Reflux (VUR): The primary mechanism in young children. During voiding, infected urine jets retrograde from bladder through incompetent ureterovesical junction into the ureter and renal pelvis. This "intrarenal reflux" delivers bacteria directly to renal parenchyma via collecting ducts in papillae. [15]

Step 5: Renal Parenchymal Inflammation & Scarring

Bacterial invasion triggers intense neutrophilic inflammation. Inflammatory mediators (IL-6, IL-8, TNF-alpha) cause:

• Acute phase: Tubular damage, interstitial edema, microabscesses
• Chronic phase: Fibrosis, cortical thinning, loss of nephrons

Critical window: The developing kidney (less than 2 years) is most vulnerable. Immature immune responses and ongoing nephrogenesis make parenchymal damage more extensive and permanent. [2,16]

Result: Focal or global renal scarring (reflux nephropathy), visible on DMSA scan as cortical defects with reduced differential function.

---

4. Vesicoureteric Reflux (VUR)

Classification (International Reflux Study Grading)

Natural History

Most VUR (Grades I-III) resolves spontaneously as the child grows. The ureterovesical junction matures, with the intramural ureteric tunnel lengthening relative to bladder size, creating an effective one-way valve. Resolution rates:

• Grade I-II: 80% resolution by age 5
• Grade III: 50% resolution by age 10
• Grade IV-V: less than 20% spontaneous resolution [15]

VUR and Renal Scarring: The Evolving Paradigm

Traditional view: VUR was considered the primary cause of renal scarring.

Modern understanding: VUR is a risk factor but is neither necessary nor sufficient for scar development. More important factors include: [4,5]

• Congenital Anomalies of Kidney and Urinary Tract (CAKUT): Renal dysplasia, multicystic dysplastic kidney
• Bladder-Bowel Dysfunction: Constipation, voiding postponement, neurogenic bladder
• Delayed treatment of pyelonephritis: Time to antibiotic initiation
• High-grade VUR (IV-V): Synergistic with infection

---

5. Definitions (NICE NG54 Framework)

Managing paediatric UTI depends critically on these definitions. [4]

Typical UTI

First episode of UTI that:

• Responds to appropriate antibiotics within 48 hours
• Is caused by E. coli
• Occurs in a systemically well child

Implication: Minimal imaging required (ultrasound only if less than 6 months).

Atypical UTI

Any ONE of the following:

1. Seriously ill (septic appearance, hypotension)
2. Poor urine flow (suggests obstruction)
3. Abdominal or bladder mass palpable
4. Raised serum creatinine (renal impairment)
5. Septicaemia (positive blood cultures)
6. Failure to respond to appropriate antibiotics within 48 hours
7. Infection with non-E. coli organisms (Proteus, Pseudomonas, Klebsiella, Staphylococcus)

Implication: Requires urgent ultrasound (during acute illness) and consideration of alternative diagnoses (obstruction, abscess, structural anomaly). [4]

Recurrent UTI

Any ONE of the following:

• ≥2 episodes of pyelonephritis (upper tract)
• 1 episode of pyelonephritis plus 1 episode of cystitis
• ≥3 episodes of cystitis (lower tract only)

Implication: Requires imaging for VUR/CAKUT, assessment for bladder-bowel dysfunction, and treatment of modifiable risk factors. Antibiotic prophylaxis is controversial and generally not recommended. [4,5]

---

6. Clinical Presentation

Golden Rule: Any unexplained fever in a child less than 5 years must prompt urine sampling. UTI is a diagnosis of exclusion in the febrile child. [6,11]

Infants (less than 3 months)

Non-specific presentation dominates:

• Fever (> 38°C) OR Hypothermia (less than 36°C)
• Vomiting / Poor feeding / Failure to thrive
• Lethargy, irritability, high-pitched cry
• Prolonged neonatal jaundice (> 14 days)
• Septic shock: Mottled skin, tachycardia, poor perfusion

Key point: These infants cannot localize infection. Pyelonephritis, meningitis, and sepsis present identically. Aggressive investigation (urine, blood, CSF) and empirical broad-spectrum antibiotics are mandatory. [6]

Pre-Verbal Children (3 months - 2 years)

• Fever (often > 39°C, prolonged > 48 hours)
• Abdominal pain (vague, non-localizing)
• Vomiting, diarrhea
• Offensive-smelling urine ("fishy" odor)
• Irritability, lethargy
• No respiratory or ENT symptoms (fever without source)

Verbal Children (> 2 years)

Lower tract (Cystitis):

• Dysuria ("it hurts when I pee")
• Frequency and urgency
• New-onset daytime or nighttime incontinence (secondary enuresis)
• Suprapubic discomfort
• Afebrile or low-grade fever

Upper tract (Pyelonephritis):

• High fever (> 38.5°C), rigors
• Loin or flank pain (may be unilateral)
• Costovertebral angle tenderness on examination
• Systemic symptoms: vomiting, malaise
• May have lower tract symptoms concurrently

---

7. Differential Diagnosis

1. The "Dysuria" Differential

Most children with dysuria do NOT have UTI. [11]

2. The "Fever Without Focus" Differential

In febrile infants with no obvious source:

3. The "Abdominal Pain" Differential

---

8. Investigations

Urine Collection Methods: Hierarchy of Accuracy

Contamination vs invasiveness trade-off: [8,17]

Critical principle: A positive bag urine cannot diagnose UTI due to high false-positive rate. Use it to exclude infection (negative predictive value 95-98%). If positive, confirm with clean-catch or catheter before starting antibiotics. [8]

Urinalysis (Dipstick)

Age-specific interpretation: [4]

Urine Microscopy & Culture

Gold Standard for UTI diagnosis. [13,17]

Microscopy findings:

• WBCs: > 10 per high-power field suggests pyuria
• Bacteria: Visible organisms on Gram stain (sensitivity 80-90%)
• WBC casts: Suggest pyelonephritis (upper tract)

Culture threshold:

• ≥10^5 CFU/mL (100,000 colonies): Diagnostic for UTI in clean-catch/midstream specimens
• ≥10^4 CFU/mL (10,000 colonies): Diagnostic for catheter specimens
• Any growth: Diagnostic for suprapubic aspirate (normally sterile)

Time to positivity: 24-48 hours for culture, 48-72 hours for sensitivities.

Growth of ≥2 organisms: Suggests contamination. Repeat sample with better technique.

Blood Investigations

Indicated if:

• Age less than 3 months
• Systemically unwell (septic appearance)
• Admitted for IV antibiotics
• Atypical features

Tests:

• Full blood count: Leucocytosis (WCC \u003e 15), left shift, thrombocytosis (inflammatory response)
• C-reactive protein (CRP): Elevated in pyelonephritis (often \u003e 50 mg/L), normal in cystitis
• Procalcitonin (PCT): Superior biomarker for distinguishing pyelonephritis from cystitis [21,22]
  • "Optimal cutoff: 1.0 ng/mL (meta-analysis: sensitivity 86%, specificity 91%, AUROC 0.94) [21]"
  • "Alternative cutoff: 1.3 ng/mL (sensitivity 86.2%, specificity 89.8%) [22]"
  • "Scarring prediction: PCT ≥0.5 ng/mL associated with late renal scarring (OR 3.4, sensitivity 79%) [23]"
  • "Advantage: Outperforms CRP and WCC for early APN diagnosis and scarring risk stratification [22,23]"
• Urea \u0026 electrolytes: Assess renal function, exclude obstructive uropathy (raised creatinine)
• Blood cultures: Positive in 5-10% of pyelonephritis cases (bacteremia)

---

9. Management

Initial Risk Stratification

Admit for IV antibiotics if:

• Age less than 3 months (risk of overwhelming sepsis)
• Clinical sepsis (shock, altered consciousness)
• Persistent vomiting (cannot tolerate oral medications)
• Severe dehydration
• Failure to respond to oral antibiotics within 24-48 hours
• Concerns about compliance or follow-up

Outpatient oral antibiotics if:

• Age > 3 months
• Systemically well, tolerating oral fluids
• Reliable caregivers, good follow-up available

Antibiotic Selection: The Resistance Challenge

Critical principle: Antibiotic resistance in pediatric UTI is rising globally and mandates local surveillance-guided therapy. [12,13,18]

Contemporary Resistance Patterns (2020-2024)

United States (2014-2023 SENTRY surveillance, n=3,511 E. coli isolates): [24]

• Trimethoprim-sulfamethoxazole: 69.7% susceptible (30.3% resistant)
• Ampicillin-sulbactam: 55.7% susceptible (44.3% resistant)
• Extended-spectrum beta-lactamase (ESBL) prevalence: Increased from 7.1% (2014) to 10.8% (2023)
• Highest resistance rates: Infants 0-24 months, Pacific census region

Europe (20-year Belgian cohort, 2000-2019): [25]

• Amoxicillin-clavulanate resistance in E. coli: Rose from 16% (2000-2004) to 36% (2015-2019)—average increase of 2.0% per year
• Third-generation cephalosporin resistance: Increased 1.1% per year
• Risk factors: Prior antibiotic use (OR 2.5), CAKUT (OR 4.26 for non-E. coli organisms)

Central Asia (Kazakhstan, 2017-2022): [26]

• Multidrug resistance (MDR): 34% overall, increasing with age (28% in infants \u003c 12 months → 43% in children 13-60 months)
• High resistance: Amoxicillin (75%), erythromycin (65%)
• Preserved susceptibility: Imipenem (94%), amikacin (90%), meropenem (87%)

Key implications:

• Trimethoprim and amoxicillin monotherapy are no longer reliable empirical choices in many regions
• ESBL prevalence is rising, particularly in young infants (highest-risk group)
• Resistance patterns vary geographically—local antibiograms essential

1. Acute Pyelonephritis (Upper Tract) - Inpatient IV

First-line options:

A. Ceftriaxone

• Dose: 50-80 mg/kg IV/IM once daily (max 2 g)
• Advantages: Once-daily dosing, excellent CSF penetration (if co-existent meningitis), broad gram-negative cover
• Disadvantages: Calcium precipitation (avoid concurrent calcium infusions), biliary sludge, C. difficile risk
• Duration: 2-4 days IV, then switch to oral (total 7-10 days)

B. Amoxicillin + Gentamicin

• Amoxicillin: 50 mg/kg IV TDS (covers Enterococcus)
• Gentamicin: 5-7 mg/kg IV/IM once daily
• Monitoring: Check gentamicin trough level before 2nd dose (less than 1 mg/L to avoid nephrotoxicity/ototoxicity)
• Advantages: Synergistic, covers resistant E. coli
• Disadvantages: Requires level monitoring, potential toxicity
• Duration: 2-4 days IV, switch to oral based on sensitivities

C. Cefotaxime (alternative to ceftriaxone)

• Dose: 50 mg/kg IV TDS
• Advantage: No calcium interaction
• Disadvantage: More frequent dosing

2. Acute Pyelonephritis - Outpatient Oral

A. Co-amoxiclav (Amoxicillin + Clavulanic Acid)

• Dose: 0.25 mL/kg TDS of 125/31 suspension (or age-specific dosing)
• Coverage: E. coli, Klebsiella, beta-lactamase producers
• Disadvantage: Diarrhea common (10-20%)
• Duration: 7-10 days (short courses fail in pyelonephritis)

B. Cefalexin (1st generation cephalosporin)

• Dose: 12.5 mg/kg TDS (max 500 mg TDS)
• Advantages: Better palatability ("strawberry flavor"), good compliance
• Coverage: Gram-negative coliforms
• Disadvantage: Does not cover Enterococcus
• Duration: 7-10 days

C. Cefixime (3rd generation oral cephalosporin)

• Dose: 8 mg/kg once daily
• Advantage: Once-daily dosing improves compliance
• Coverage: Extended gram-negative spectrum

3. Lower UTI (Cystitis) - Oral

Shorter duration (3 days) adequate for uncomplicated lower tract infection. [4,18]

A. Nitrofurantoin

• Dose: 0.75 mg/kg QDS (or 1 mg/kg BD for modified-release)
• Advantages: Very low resistance rates (less than 5%), bactericidal in urine
• Contraindications:
  • Renal impairment (eGFR less than 45 - inadequate urine concentration)
  • G6PD deficiency (risk of hemolysis)
  • Age less than 3 months (immature enzyme systems)
• Duration: 3 days

C. Trimethoprim

• Dose: 4 mg/kg BD (max 200 mg BD)
• Resistance: Rising worldwide (30-40% E. coli resistance in UK, 30.3% in U.S.) [18,24]
• Risk factors for resistance: Prior antibiotic use within 6 months, recurrent UTI, recent hospitalization
• Use: Only if local resistance less than 20% (no longer recommended as empirical first-line in most regions)
• Duration: 3 days

C. Cefalexin

• Dose: 12.5 mg/kg BD-TDS
• Duration: 3 days

IV to Oral Switch Criteria

Switch when:

• Afebrile for 24 hours
• Tolerating oral fluids
• Clinically improving (eating, playful)
• Urine culture sensitivities available (target therapy)

Total duration: 7-10 days for pyelonephritis, 3 days for cystitis.

Supportive Care

• Analgesia: Paracetamol or ibuprofen for fever/pain
• Hydration: Encourage oral fluids, IV fluids if vomiting/dehydrated
• Antipyretics: Treat fever > 38.5°C for comfort

Follow-Up

• Clinical review at 24-48 hours (outpatient) or daily ward rounds (inpatient)
• Ensure urine culture sensitivities reviewed and antibiotics adjusted
• Repeat urine culture not routinely required if clinical improvement
• Arrange imaging as per protocol (see Section 10)

---

10. Imaging Strategy: The NICE NG54 Protocol

Philosophy: Minimize radiation exposure while detecting clinically significant structural anomalies. [4,19]

Key principle: Not all children with UTI need imaging. Risk-stratify based on age and UTI characteristics.

The Imaging Decision Matrix

Rationale for age differences:

• less than 6 months: Highest risk of CAKUT, VUR, and renal scarring. More aggressive imaging.
• > 6 months: Lower CAKUT prevalence. Imaging reserved for atypical/recurrent infections.

Imaging Modalities: Deep Dive

1. Renal Ultrasound (USS)

Purpose: Anatomical screening for structural anomalies.

What it detects:

• Hydronephrosis (dilated renal pelvis > 5 mm)
• Hydroureter (dilated ureter)
• Bladder wall thickening (> 3 mm suggests chronic changes)
• Renal size asymmetry (> 1 cm difference suggests scarring or dysplasia)
• Stones, masses, multicystic dysplastic kidney

Limitations:

• Cannot detect renal scarring (parenchymal defects too subtle)
• Cannot detect VUR (functional abnormality, not structural)
• Operator-dependent

Advantages:

• No ionizing radiation
• Non-invasive, no sedation required
• Widely available

Timing:

• During acute infection (if atypical): To detect obstruction, abscess
• 6 weeks post-infection (if typical in less than 6 months): Allows acute inflammation to settle

2. DMSA Scan (Dimercaptosuccinic Acid Scintigraphy)

Purpose: Gold standard for detecting renal scarring and assessing differential renal function. [19,20]

Technique:

1. Inject Technetium-99m DMSA IV (radiotracer)
2. DMSA binds to proximal tubular cells
3. Gamma camera acquires static images 2-4 hours post-injection
4. Areas of normal cortex appear "hot" (radiotracer uptake)
5. Scars appear as "cold spots" (photopenic defects—no uptake)

Critical timing: 4-6 months after acute UTI. [4,19]

• Why wait? Acute pyelonephritis causes transient inflammation that mimics scarring on early scans (false positives). Waiting allows inflammation to resolve—persistent defects represent permanent scarring.

Results interpretation:

• Differential function: Left kidney 50% / Right kidney 50% is normal
  • Asymmetry (e.g., 30%/70%) suggests unilateral scarring or hypoplasia
  • "Severe scarring: less than 10% function in one kidney"
• Cortical defects: Focal photopenic areas indicate scarring
• Small kidney: Growth arrest from chronic damage

Radiation dose: Equivalent to 4 months of background radiation or 1 trans-Atlantic flight. [19]

Implications:

• If scarring detected: Long-term BP monitoring, proteinuria screening, nephrology follow-up
• If no scarring: Reassurance, no long-term sequelae expected

3. MCUG (Micturating Cystourethrogram)

Purpose: Gold standard for detecting vesicoureteric reflux (VUR) and grading severity. [15]

Technique:

1. Urethral catheterization (traumatic, distressing)
2. Fill bladder with radio-opaque contrast via catheter
3. Fluoroscopy during filling and voiding
4. Child must void on examination table (difficult in young children)
5. Observe for retrograde flow of contrast into ureters/kidneys

Indications (highly selective, per NICE): [4]

• Age less than 6 months with atypical or recurrent UTI
• Abnormal renal ultrasound (hydronephrosis, scarring)
• Non-E. coli infection (suggests structural problem)
• Not routine for typical first UTI

Complications:

• Iatrogenic UTI (catheter introduction of bacteria): 5-10% risk
• Prophylaxis required: Trimethoprim or cefalexin for 3 days peri-procedure
• Psychological trauma (catheterization, radiation exposure)

Why restrictive use?: [5]

• VUR detection does not change management in most cases (prophylaxis no longer routine)
• Most low-grade VUR resolves spontaneously
• Radiation exposure (gonadal dose significant)
• Invasive and distressing procedure

4. MAG3 Renogram (Alternative to DMSA)

Purpose: Dynamic renal scan to assess obstruction (e.g., pelviureteric junction obstruction).

Technique:

• Inject Technetium-99m MAG3 (mercaptoacetyltriglycine)
• Gamma camera tracks tracer transit through kidneys
• Administer furosemide (washout phase)
• Obstructed kidney shows delayed washout (tracer accumulates)

Curve patterns:

• Normal: Rapid uptake and washout (T½ less than 10 minutes)
• Obstructed: Delayed washout (T½ > 20 minutes)
• Dilated non-obstructed: Intermediate washout

Use: Reserved for hydronephrosis detected on ultrasound to differentiate obstruction from benign dilation.

---

11. Management of Vesicoureteric Reflux

The Paradigm Shift: Conservative Management

Historical approach: Detect VUR via MCUG → Long-term antibiotic prophylaxis → Surgical correction

Modern evidence-based approach: [4,5,15]

• VUR is a risk factor, not a disease requiring treatment
• Most VUR (Grades I-III) resolves spontaneously with maturation
• Antibiotic prophylaxis does NOT prevent renal scarring (multiple RCTs)
• Focus on modifiable risk factors: bladder-bowel dysfunction, voiding habits, prompt UTI treatment

Antibiotic Prophylaxis: The Controversy

NICE NG54 recommendation (2007, updated 2022): Prophylaxis generally NOT recommended. [4]

Evidence:

• RIVUR trial (2014): Prophylaxis reduced recurrent UTI by 50% but did NOT reduce renal scarring
• PRIVENT trial (2009): No benefit of prophylaxis for VUR
• Concerns: Antibiotic resistance, adverse effects, poor compliance

Exceptions (consider prophylaxis):

• High-grade VUR (IV-V) with recurrent febrile UTIs
• Severe bladder-bowel dysfunction refractory to treatment
• Parental anxiety after counseling (shared decision-making)

Prophylaxis regimen (if used):

• Trimethoprim: 2 mg/kg once daily at night
• Nitrofurantoin: 1 mg/kg once daily at night (avoid if eGFR less than 45)
• Duration: 6-12 months, then reassess

Surgical Options for VUR

Indications (highly selective):

• High-grade VUR (IV-V) with recurrent breakthrough UTIs on prophylaxis
• Progressive renal scarring despite medical management
• Parental preference (after detailed counseling)

Option 1: Endoscopic Subureteric Injection (Deflux)

Technique:

• Cystoscopy under general anesthesia
• Inject bulking agent (dextranomer/hyaluronic acid gel—NASHA/Dx) submucosally at ureteric orifice
• Creates artificial "valve" to prevent reflux

Success rate: [27,28]

• First injection: 69-70% for Grades III-IV VUR, 62% for Grade V
• After 2-3 injections: Cumulative resolution 100% (no reimplantation required)
• Long-term (15-25 year follow-up): 75% avoid reimplantation, low recurrent UTI risk (10%), bladder dysfunction (34%) [27]

Advantages:

• Minimally invasive (day-case procedure)
• Low morbidity
• Can repeat if fails
• Durable long-term results (technique-dependent)

Disadvantages:

• Lower success than open surgery for Grade V
• May need multiple injections (10-20% require second, 10% require third)
• Delayed ureteral obstruction reported (rare, less than 2%)
• Learning curve for optimal injection technique

Predictors of failure: [27,28]

• Age less than 1 year at treatment
• Pre-existing renal scarring
• Grade V VUR
• Suboptimal injection volume/technique

Option 2: Open Ureteric Reimplantation

Technique:

• Detach ureter from bladder
• Create longer submucosal tunnel (3-5 cm)
• Re-implant ureter with new angle (anti-reflux mechanism)
• Techniques: Cohen (cross-trigonal), Politano-Leadbetter, Lich-Gregoir

Success rate: 95-98%

Advantages:

• Definitive cure
• Durable long-term results

Disadvantages:

• Major surgery (3-5 day admission)
• Ureteric obstruction risk (1-2%)
• Bladder spasms, hematuria postoperatively

---

12. Constipation & Bladder-Bowel Dysfunction

The Rectum-Bladder Connection

Pathophysiology: A rectum loaded with stool compresses the bladder anteriorly, causing:

• Detrusor instability: Uninhibited bladder contractions
• Incomplete emptying: Urinary stasis (bacterial growth)
• Recurrent UTIs: 60-80% of children with recurrent UTI have constipation [7]

Management Strategy

First-line: Treat constipation aggressively. [7]

Step 1: Assessment

• Bristol Stool Chart (Type 1-2 = constipated)
• Abdominal palpation (faecal loading in left iliac fossa)
• History: Frequency, withholding behaviors, painful defecation

Step 2: Disimpaction (if fecal loading present)

Movicol Paediatric Plain (polyethylene glycol + electrolytes):

• Escalating regimen:
  • "Day 1: 2 sachets"
    • Day 2: 4 sachets
  • "Day 3: 6 sachets"
  • Continue at 6-12 sachets/day until disimpacted (loose, watery stools)
• Duration: Usually 7-14 days

Step 3: Maintenance Therapy

Movicol Paediatric: 1-2 sachets daily (adjust to achieve soft, regular stools)

Lactulose: 5-10 mL BD (osmotic laxative, less effective than Movicol)

Senna: Add stimulant laxative if osmotic therapy insufficient

Step 4: Behavioral Interventions

• Timed voiding: Toilet every 3 hours (prevents urinary stasis)
• Double voiding: Void, wait 2 minutes, void again (ensures complete emptying)
• Adequate fluid intake: 6-8 cups/day
• Dietary fiber: Fruits, vegetables, whole grains
• Toilet posture: Feet supported on stool (relaxes pelvic floor)

Goal: Resolve constipation first, then UTIs will often cease without further intervention.

---

13. Complications & Long-Term Outcomes

1. Renal Scarring (Reflux Nephropathy)

Incidence: 5-15% of children with first febrile UTI develop scarring detectable on DMSA. [2,20]

Risk factors:

• Age less than 2 years (developing kidney most vulnerable)
• Delayed treatment (> 4 days from symptom onset to antibiotics)
• High-grade VUR (IV-V)
• Recurrent pyelonephritis
• Virulent bacterial strains (P fimbriae-positive E. coli)

Pathophysiology:

• Intrarenal reflux → Bacterial entry into collecting ducts → Tubular damage → Inflammatory cascade → Fibrosis → Cortical thinning

Result: Focal or global scarring, reduced nephron mass, growth arrest of affected kidney

Long-term consequences:

A. Hypertension

• Incidence: 10-20% of children with bilateral scarring develop hypertension by adolescence [2]
• Mechanism: Reduced renal perfusion → Renin-angiotensin activation (renovascular hypertension)
• Management: Annual BP monitoring, ACE inhibitors if hypertensive

B. Proteinuria

• Glomerular hyperfiltration injury (remaining nephrons overwork)
• Increased intraglomerular pressure → Podocyte damage → Protein leak
• May progress to nephrotic-range proteinuria

C. Chronic Kidney Disease (CKD)

• Reflux nephropathy accounts for 5-15% of children requiring dialysis/transplantation [2]
• Risk factors: Bilateral scarring, solitary kidney, recurrent UTIs
• Pregnancy implications: Women with reflux nephropathy have increased risk of pre-eclampsia, fetal growth restriction, preterm delivery

2. Urosepsis & Septic Shock

Incidence: 1-5% of febrile UTIs progress to sepsis, higher in neonates and children with CAKUT

Mechanism: Bacterial translocation from urinary tract → Bloodstream → Systemic inflammatory response

Presentation:

• Fever or hypothermia
• Tachycardia, hypotension
• Mottled skin, prolonged capillary refill (> 3 seconds)
• Altered consciousness, lethargy
• Oliguria (urine output less than 1 mL/kg/hr)

Management:

• ABC resuscitation: High-flow oxygen, IV fluid boluses (20 mL/kg crystalloid)
• Empirical antibiotics: Ceftriaxone 80 mg/kg IV + Gentamicin 7 mg/kg IV (within 1 hour)
• Sepsis Six bundle: Blood cultures, lactate, urine output monitoring
• Escalate to PICU if shock persists

Mortality: less than 1% in developed countries with prompt treatment; 5-10% if delayed

3. Renal Abscess

Incidence: Rare (less than 1%), usually complication of obstructive uropathy or hematogenous seeding (Staphylococcus aureus)

Presentation:

• Persistent fever despite 48-72 hours of appropriate antibiotics
• Swinging pyrexia (temperature spikes)
• Loin pain, palpable mass
• Elevated inflammatory markers (CRP > 100 mg/L)

Diagnosis: Contrast-enhanced CT or MRI (USS may miss small abscesses)

Management:

• Antibiotics: Prolonged course (4-6 weeks), IV initially
• Drainage: Percutaneous or surgical if > 3 cm or not responding

4. Xanthogranulomatous Pyelonephritis

Rare chronic destructive infection associated with stones, obstruction, Proteus or E. coli

Presentation: Recurrent UTIs, failure to thrive, flank mass

Diagnosis: CT shows enlarged kidney with low-attenuation areas (lipid-laden macrophages)

Management: Nephrectomy (non-functional kidney)

---

14. Prevention Strategies

1. Hygiene & Voiding Habits

For girls:

• Wipe front to back (prevents fecal contamination of urethra)
• Avoid bubble baths and scented soaps (cause urethral irritation)
• Avoid tight clothing (creates warm, moist environment)

For all children:

• Timed voiding: Toilet every 3 hours (prevents urinary stasis)
• Complete bladder emptying: Avoid "holding" urine
• Post-defecation voiding: Void after bowel movement (empties any refluxed urine)
• Adequate hydration: 6-8 cups/day (dilutes urine, increases washout)

2. Circumcision

Evidence: Strong and consistent. [9,10]

Meta-analysis (2023): Circumcision reduces UTI incidence by 72% (pooled OR 0.28, 95% CI 0.23-0.32) in boys with antenatal hydronephrosis. Effect size greatest in first year of life. [10]

Mechanism:

• Removes preputial bacterial reservoir (E. coli, Proteus colonize smegma)
• Eliminates phimosis (urinary stasis behind tight foreskin)

Policy:

• Not routine in UK/Australia (not NHS-funded)
• Therapeutic circumcision justified for:
  • Recurrent UTIs in boys with confirmed VUR or hydronephrosis
  • Severe phimosis or balanitis xerotica obliterans (BXO)
  • Recurrent balanitis

Number Needed to Treat (NNT):

• NNT = 111 to prevent one UTI in normal boys (first year)
• NNT = 4-7 in boys with high-grade VUR or hydronephrosis

3. Cranberry Products

Theory: Proanthocyanidins (PACs) prevent bacterial adherence to uroepithelium

Evidence: Weak/Inconclusive for paediatric UTI prevention [11]

Cochrane Review (2012): No significant reduction in recurrent UTI in children (RR 0.75, 95% CI 0.39-1.44, not statistically significant)

Concerns:

• High sugar content (promotes dental caries, obesity)
• Poor palatability in children
• Variable PAC concentration across products
• Drug interactions (warfarin)

Recommendation: Not routinely recommended. May consider in motivated families as adjunct to other measures.

4. Probiotics (Lactobacillus)

Theory: Restore healthy urogenital flora, competitive exclusion of uropathogens

Evidence: Limited pediatric data. Small studies suggest possible benefit for recurrent UTI but methodological flaws. [11]

Recommendation: Insufficient evidence for routine use. Research ongoing.

5. Vitamin D Supplementation

Emerging evidence: Vitamin D deficiency associated with increased UTI risk (immune modulation)

Status: Preliminary data only, no formal recommendations yet

---

15. Examination Focus: OSCEs & Vivas

OSCE Station: Explaining DMSA Scan to Parents

Scenario: "Doctor, why does my child need a radioactive scan? Isn't radiation dangerous?"

Model Answer:

Step 1: Validate concerns "I completely understand your worry about radiation—it's a very natural concern, and I'm glad you've raised it."

Step 2: Explain the "why" "After a kidney infection in young children, we need to check if the infection has left any permanent scars on the kidney. An ultrasound can show the kidney's shape and size, but it cannot detect scars within the kidney tissue. The DMSA scan is the only test that can show us if there's any damage."

Step 3: Quantify the risk "The amount of radiation from this scan is very small—equivalent to about 4 months of natural background radiation that we're all exposed to every day, or roughly the same as a long-haul flight to Australia. For comparison, a chest X-ray is about 1 week of background radiation."

Step 4: Explain the benefit "If we find a scar, we can monitor your child's blood pressure and kidney function as they grow. If scar tissue has reduced kidney function, we may need to protect the remaining kidney more carefully. If we don't do the scan, we won't know if there's a problem until symptoms appear—by which time it may be harder to manage."

Step 5: Address alternatives "We only recommend this scan when it's really necessary. We've moved away from doing lots of tests in all children—only those at higher risk, like [your child's specific reason: recurrent infection/atypical infection/young age]."

Step 6: Shared decision-making "The decision is ultimately yours. Would you like some time to think about it, or do you have any other questions I can answer?"

Viva: Define "Atypical UTI"

Examiner: "A 7-month-old presents with her first UTI. What features would make this 'atypical'?"

Candidate (structured response):

"Atypical UTI, as defined by NICE guideline NG54, includes any one of the following features:

1. Severity: Seriously ill or septic appearance

2. Obstruction: Poor urine flow or palpable bladder/abdominal mass

3. Renal impairment: Raised serum creatinine

4. Systemic spread: Septicaemia or bacteremia

5. Treatment failure: Failure to respond to appropriate antibiotics within 48 hours

6. Organism: Infection with non-E. coli organisms such as Proteus, Pseudomonas, or Klebsiella

The presence of atypical features mandates urgent ultrasound during the acute illness to exclude obstruction, stones, or abscess. It also triggers consideration of DMSA scan at 4-6 months and, in infants under 6 months, possibly MCUG to detect VUR."

Examiner: "Why does a non-E. coli organism make it atypical?"

Candidate: "Non-E. coli organisms, particularly Proteus and Pseudomonas, are associated with structural abnormalities such as:

• Stones: Proteus produces urease, which alkalinizes urine and precipitates struvite stones
• CAKUT: Duplex systems, posterior urethral valves
• Recent instrumentation or catheters

Their presence suggests the UTI is not a simple ascending infection but may reflect an underlying anatomical problem that requires imaging to detect."

Viva: Antibiotic Prophylaxis for VUR

Examiner: "The child is found to have Grade III VUR on MCUG. Would you start antibiotic prophylaxis?"

Candidate:

"The role of antibiotic prophylaxis for VUR has evolved significantly, and current evidence does not support routine use.

Evidence:

• The RIVUR trial (2014) showed prophylaxis reduced recurrent UTI by approximately 50%, but crucially, it did not reduce renal scarring rates—the outcome we most want to prevent.
• The PRIVENT trial similarly found no benefit in preventing scarring.

NICE NG54 recommendation: Prophylaxis is generally not recommended.

My approach would be:

1. Assess modifiable risk factors:

• Is there bladder-bowel dysfunction or constipation? (Treat aggressively with laxatives)
• Are voiding habits suboptimal? (Institute timed voiding, adequate hydration)

2. Parental education:

• Recognize UTI symptoms early
• Seek prompt medical attention
• Ensure antibiotic compliance if UTI occurs

3. Surveillance:

• DMSA scan at 4-6 months to assess for scarring
• If scarring present, long-term BP monitoring

4. Exceptions (consider prophylaxis):

• Recurrent breakthrough UTIs despite optimization of bladder-bowel function
• High-grade VUR (IV-V) with recurrent febrile infections
• Parental anxiety after detailed discussion (shared decision-making)

If prophylaxis is used, I would prescribe trimethoprim 2 mg/kg once daily at night or nitrofurantoin 1 mg/kg once daily (if eGFR normal), for 6-12 months, with review."

Viva: PCT vs CRP for Pyelonephritis Diagnosis

Examiner: "A 2-year-old presents with first febrile UTI. Should you measure procalcitonin?"

Candidate:

"Procalcitonin is an emerging biomarker with superior diagnostic accuracy compared to traditional markers for distinguishing acute pyelonephritis from lower UTI.

Evidence:

• Meta-analysis (Zhang 2016) [21]: Optimal PCT cutoff of 1.0 ng/mL yields sensitivity 86%, specificity 91%, and AUROC 0.94—significantly better than CRP.
• Clinical validation (Chen 2013) [22]: PCT cutoff 1.3 ng/mL showed 86.2% sensitivity and 89.8% specificity for APN.
• Scarring prediction (Leroy 2013) [23]: PCT ≥0.5 ng/mL predicts late renal scarring with OR 3.4.

Advantages over CRP:

• Earlier rise (within 4 hours vs 12-24 hours for CRP)
• Higher specificity for bacterial infection (less elevation in viral illness)
• Predicts both acute pyelonephritis and future scarring risk

Clinical utility:

• Helps triage children for inpatient vs outpatient management
• Guides imaging decisions (high PCT → higher scarring risk → consider DMSA)
• May reduce unnecessary DMSA scans in low-risk cases

Limitations:

• Not universally available (cost, lab processing time)
• Should complement, not replace, clinical assessment
• Cutoff values vary across studies

I would consider PCT measurement in equivocal cases where distinguishing upper from lower tract infection affects management (e.g., deciding IV vs oral antibiotics, admission vs discharge)."

---

16. Clinical Case Studies

Case 1: The Febrile Neonate

Presentation: 6-week-old male infant, presented to ED with 24-hour history of fever (39.2°C), poor feeding, and one episode of vomiting. Born at term, no antenatal concerns. Uncircumcised.

Examination: Temperature 39.1°C, HR 170 bpm, RR 50/min, capillary refill 2 seconds. Alert but irritable when handled. Anterior fontanelle soft, not bulging. Chest clear. Abdomen soft, no organomegaly.

Initial management: Septic screen: Blood culture, urine (catheter specimen), lumbar puncture (CSF) Urine dipstick: Leucocytes +++, Nitrites + Empirical antibiotics: IV Ceftriaxone 50 mg/kg + IV Gentamicin 5 mg/kg (covers UTI, meningitis, sepsis) Admission: Neonatal unit for observation

Results (24 hours):

• Urine culture: > 10^5 CFU/mL E. coli (sensitive to ceftriaxone, gentamicin, co-amoxiclav)
• Blood culture: Negative
• CSF: Normal cell count, protein, glucose—culture negative

Diagnosis: Febrile UTI (pyelonephritis likely given high fever)

Definitive treatment:

• Continue IV ceftriaxone 50 mg/kg OD for 3 days
• Switch to oral co-amoxiclav 0.25 mL/kg TDS when afebrile and feeding well
• Total 10 days antibiotics

Imaging (per NICE NG54, age less than 6 months with typical UTI):

• Renal ultrasound at 2 weeks: Normal kidneys, no hydronephrosis, no structural anomaly
• DMSA scan: Not indicated (first typical UTI, normal USS)
• MCUG: Not indicated (typical UTI)

Outcome: Complete recovery, no recurrence at 12-month follow-up

Learning points:

• Age less than 3 months = septic screen + admission + IV antibiotics (cannot exclude meningitis clinically)
• Uncircumcised male infants have 20% UTI prevalence when febrile
• Normal USS after first typical UTI in infant = no further imaging needed
• Neonatal UTI pearls: Hypothermia as common as fever; prolonged jaundice may be only sign; CSF examination mandatory (concurrent meningitis in 5-10%)

---

Case 2: The Constipated Recurrence

Presentation: 4-year-old girl, 4th UTI in 8 months. Mother states "she's fine between infections, goes to toilet normally."

Targeted history:

• Bowel movements: Every 2-3 days, "sometimes very large stools that block the toilet"
• Withholding behavior: Crosses legs, tiptoes when needs to defecate
• Abdomen: Mother reports "hard tummy sometimes"
• Voiding: Rushes to toilet at last minute, sometimes "dances around"

Examination: Abdomen: Palpable fecal masses in left iliac fossa and descending colon (faecal loading)

Diagnosis:

• Recurrent UTI (definition met: > 3 cystitis episodes)
• Functional constipation with bladder-bowel dysfunction (primary driver)

Investigations:

• Urine culture: E. coli (current UTI)
• Renal USS (done after 2nd UTI): Normal
• DMSA scan (arranged for 4 months): Showed small cortical scar upper pole left kidney (10% differential function loss)

Management:

1. Treat acute UTI: Trimethoprim 4 mg/kg BD for 3 days

2. Aggressive constipation management:

• Disimpaction: Movicol Paediatric escalating dose (2→4→6→8 sachets/day until clear)
• Maintenance: Movicol 2 sachets daily, titrate to Bristol Type 4 stools
• Dietary advice: Increase fiber (fruits, vegetables), adequate hydration (6 cups/day)

3. Bladder retraining:

• Timed voiding: Toilet every 3 hours (set alarm on watch)
• Double voiding: Void, wait 2 minutes, void again
• Footstool: Use stool to support feet on toilet (relaxes pelvic floor)

4. Antibiotic prophylaxis: Considered but not started (per NICE—emphasis on treating constipation first)

Outcome:

• Constipation resolved over 3 months
• Zero UTIs in subsequent 18 months
• DMSA scar stable on repeat scan (no progression)

Learning points:

• Always ask about bowel habit in recurrent UTI (80% have constipation)
• Loaded rectum → Bladder compression → Incomplete emptying → Urinary stasis → UTI
• Cannot cure UTI without curing constipation
• Prophylaxis often unnecessary if underlying dysfunction corrected
• Voiding dysfunction spectrum: Ranges from infrequent voiding ("holding on all day at school") to neurogenic bladder; always assess voiding diary (frequency, volume, urgency episodes)

---

Case 3: The Atypical Organism

Presentation: 7-month-old girl, first UTI, treated with co-amoxiclav. Still febrile at 72 hours.

Culture results: Proteus mirabilis > 10^5 CFU/mL (resistant to co-amoxiclav, sensitive to ceftriaxone, gentamicin)

Atypical features:

1. Non-E. coli organism (Proteus)
2. Failure to respond within 48 hours

Immediate action:

• Switch antibiotics to IV Ceftriaxone 80 mg/kg OD (based on sensitivities)
• Urgent renal ultrasound (same day)

USS findings:

• Right hydronephrosis (anteroposterior renal pelvic diameter 12 mm)
• Dilated ureter
• Normal left kidney

Further imaging:

• MCUG (performed 4 weeks post-infection): Grade IV vesicoureteric reflux on right side
• DMSA scan (4 months post-infection): Cortical scar upper and mid-pole right kidney (30% differential function right, 70% left)

Management:

1. Antibiotics: Completed 10-day course IV then oral ceftriaxone

2. Urology referral: For high-grade VUR management

3. Antibiotic prophylaxis: Started (exception to NICE—high-grade VUR + scarring + age less than 1 year)

• Trimethoprim 2 mg/kg once nightly

4. Constipation prevention: Optimize bladder-bowel function

5. Surveillance:

• Repeat USS every 6 months (monitor hydronephrosis)
• Annual BP checks (hypertension risk)
• Proteinuria screening (urine dipstick 6-monthly)

6. Surgical decision: Awaiting 12-month trial of prophylaxis

• If breakthrough UTI → Consider ureteric reimplantation or Deflux injection
• If stable → Continue surveillance, may resolve with growth

Outcome (12 months):

• One breakthrough UTI despite prophylaxis
• Parents opted for endoscopic Deflux injection (successful)
• No further UTIs, VUR downgraded to Grade II on repeat MCUG

Learning points:

• Non-E. coli organism = Atypical UTI → Urgent imaging
• Proteus associated with stones (urease producer) and structural anomalies
• Failure to respond to antibiotics within 48 hours = Check sensitivities + Change antibiotic + Urgent USS
• High-grade VUR + scarring = Exception to "no prophylaxis" rule (individualized decision)
• Atypical organisms as red flags: Pseudomonas suggests immunodeficiency or recent instrumentation; Proteus alkalinizes urine (pH \u003e 8) promoting struvite stone formation; Klebsiella more common in diabetes/immunosuppression

---

17. Prognosis & Long-Term Follow-Up

Children Without Scarring (DMSA negative)

Excellent prognosis:

• No increased risk of hypertension
• No increased risk of CKD
• Normal life expectancy and renal function
• Discharge from nephrology follow-up after normal DMSA at 4-6 months

Children With Renal Scarring (DMSA positive)

Long-term surveillance required: [2,20]

Transition to Adult Services

Criteria for long-term nephrology follow-up:

• Bilateral renal scarring
• Reduced differential function (less than 40% in one kidney)
• Hypertension or proteinuria
• High-grade VUR (IV-V) not resolved

Transfer to adult nephrology at age 16-18 years with comprehensive transition plan.

---

18. Audit Standards (NICE NG54 Quality Indicators)

---

19. Summary: High-Yield Exam Points

Must-Know Statistics (Cite in Vivas)

1. Prevalence: 7% of febrile infants have UTI; 20% if uncircumcised male less than 3 months [3]
2. E. coli: 80-90% of paediatric UTI [12,13]
3. Circumcision: Reduces UTI risk by 72-90% (OR 0.28) [9,10]
4. Scarring: 5-15% after first febrile UTI [2,20]
5. Hypertension: 10-20% with bilateral scars [2]
6. Procalcitonin: Cutoff 1.0 ng/mL (sensitivity 86%, specificity 91%) for pyelonephritis diagnosis [21,22]
7. Antibiotic resistance: ESBL E. coli prevalence increased from 7.1% (2014) to 10.8% (2023) in U.S. [24]
8. Amoxicillin-clavulanate resistance: Rising 2% per year in Europe (16% → 36% over 20 years) [25]

Must-Know Classifications

1. VUR Grading (I-V, International Reflux Study)
2. Atypical UTI (7 criteria, NICE NG54)
3. Recurrent UTI (≥2 pyelonephritis, 1 pyelonephritis + 1 cystitis, ≥3 cystitis)

Must-Know Management Algorithms

1. Age less than 3 months with fever: Septic screen + IV antibiotics (cannot exclude meningitis)
2. Imaging decision tree: Age-stratified (NICE NG54 table)
3. Antibiotic duration: 7-10 days pyelonephritis, 3 days cystitis
4. Prophylaxis: Generally NOT recommended (NICE); exceptions: high-grade VUR + recurrent UTI

Must-Know Pitfalls

1. Bag urine: Can exclude (if negative) but cannot diagnose (if positive)
2. Nitrofurantoin in renal impairment: Contraindicated (needs GFR \u003e 45)
3. DMSA timing: Must wait 4-6 months (acute inflammation = false positive scar)
4. Constipation: 80% of recurrent UTI—must address bowel to cure bladder
5. Trimethoprim monotherapy: No longer reliable empirical choice (30-40% resistance globally)
6. Procalcitonin for scarring prediction: PCT ≥0.5 ng/mL identifies children at higher risk for late renal scarring [23]

---

20. References

1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113 Suppl 1A:5S-13S. doi:10.1016/s0002-9343(02)01054-9

2. Simões e Silva AC, Oliveira EA, Mak RH. Urinary tract infection in pediatrics: an overview. J Pediatr (Rio J). 2020;96 Suppl 1:65-79. doi:10.1016/j.jped.2019.10.006

3. Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J. 2008;27(4):302-8. doi:10.1097/INF.0b013e31815e4122

4. National Institute for Health and Care Excellence. Urinary tract infection in under 16 s: diagnosis and management. NICE guideline [NG54]. 2007 (updated 2022). https://www.nice.org.uk/guidance/ng54

5. Buettcher M, Trueck J, Niederer-Loher A, et al. Swiss consensus recommendations on urinary tract infections in children. Eur J Pediatr. 2021;180(3):663-674. doi:10.1007/s00431-020-03714-4

6. Larcombe J. Urinary tract infection in children. Am Fam Physician. 2010;82(10):1252-6.

7. Shaikh N, Hoberman A, Wise B, et al. Dysfunctional elimination syndrome: is it related to urinary tract infection or vesicoureteral reflux diagnosed early in life? Pediatrics. 2003;112(5):1134-7. doi:10.1542/peds.112.5.1134

8. American Academy of Pediatrics. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595-610. doi:10.1542/peds.2011-1330

9. Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. Arch Dis Child. 2005;90(8):853-8. doi:10.1136/adc.2004.049353

10. Wahyudi I, Raharja PAR, Situmorang GR, Rodjani A. Circumcision reduces urinary tract infection in children with antenatal hydronephrosis: Systematic review and meta-analysis. J Pediatr Urol. 2023;19(1):66-74. doi:10.1016/j.jpurol.2022.10.029

11. Leung AKC, Wong AHC, Leung AAM, Hon KL. Urinary tract infections in children. Recent Pat Inflamm Allergy Drug Discov. 2019;13(1):2-18. doi:10.2174/1872213X13666181228154940

12. Simões e Silva AC, Oliveira EA. Update on the approach of urinary tract infection in childhood. J Pediatr (Rio J). 2015;91(6 Suppl 1):S2-10. doi:10.1016/j.jped.2015.05.003

13. Haller M, Brandis M, Berner R. Antibiotic resistance of urinary tract pathogens and rationale for empirical intravenous therapy. Pediatr Nephrol. 2004;19(9):982-6. doi:10.1007/s00467-004-1525-8

14. Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595-610. doi:10.1542/peds.2011-1330

15. Skoog SJ, Peters CA, Arant BS Jr, et al. Vesicoureteral reflux outcomes. J Urol. 2010;184(4):1281-9. doi:10.1016/j.juro.2010.06.052

16. Hewitt IK, Zucchetta P, Rigon L, et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials. Pediatrics. 2008;122(3):486-90. doi:10.1542/peds.2007-2894

17. Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol. 2015;67(3):546-58. doi:10.1016/j.eururo.2014.11.007

18. Edlin RS, Shapiro DJ, Hersh AL, Copp HL. Antibiotic resistance patterns of outpatient pediatric urinary tract infections. J Urol. 2013;190(1):222-7. doi:10.1016/j.juro.2013.01.069

19. Piepsz A, Blaufox MD, Gordon I, et al. Consensus on renal cortical scintigraphy in children with urinary tract infection. Semin Nucl Med. 1999;29(2):160-74. doi:10.1016/s0001-2998(99)80005-3

20. Faust WC, Diaz M, Pohl HG. Incidence of post-pyelonephritic renal scarring: a meta-analysis of the dimercapto-succinic acid literature. J Urol. 2009;181(1):290-7. doi:10.1016/j.juro.2008.09.039

21. Zhang H, Yang J, Lin L, Huo B, Dai H, He Y. Diagnostic value of serum procalcitonin for acute pyelonephritis in infants and children with urinary tract infections: an updated meta-analysis. World J Urol. 2016;34(3):431-41. doi:10.1007/s00345-015-1630-4

22. Chen SM, Chang HM, Hung TW, et al. Diagnostic performance of procalcitonin for hospitalised children with acute pyelonephritis presenting to the paediatric emergency department. Emerg Med J. 2013;30(5):406-10. doi:10.1136/emermed-2011-200808

23. Leroy S, Fernandez-Lopez A, Nikfar R, et al. Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI. Pediatrics. 2013;131(5):870-9. doi:10.1542/peds.2012-2408

24. Mahajan S, Kanwar N, Morgan GM, et al. Antimicrobial Susceptibility Trends in E. coli Causing Pediatric Urinary Tract Infections in the United States. Pathogens. 2024;13(12):1068. doi:10.3390/pathogens13121068

25. Dejonckheere Y, Desmet S, Knops N. A study of the 20-year evolution of antimicrobial resistance patterns of pediatric urinary tract infections in a single center. Eur J Pediatr. 2022;181(9):3271-3281. doi:10.1007/s00431-022-04538-0

26. Yeleupayeva S, Dinmukhamedova A, Aizman R, et al. Current Trends in Antibiotic Resistance Patterns of Pathogens in Urinary Tract Infections in Children in Karaganda, Kazakhstan. Iran J Med Sci. 2025;50(11):788-798. doi:10.30476/ijms.2025.105826.3980

27. Stenbäck A, Olafsdottir T, Sköldenberg E, et al. Proprietary non-animal stabilized hyaluronic acid/dextranomer gel (NASHA/Dx) for endoscopic treatment of grade IV vesicoureteral reflux: Long-term observational study. J Pediatr Urol. 2020;16(3):328.e1-328.e9. doi:10.1016/j.jpurol.2020.04.008

28. Friedmacher F, Colhoun E, Puri P. Endoscopic Injection of Dextranomer/Hyaluronic Acid as First Line Treatment in 851 Consecutive Children with High Grade Vesicoureteral Reflux: Efficacy and Long-Term Results. J Urol. 2018;200(3):650-655. doi:10.1016/j.juro.2018.03.074

---

Last Updated: 2026-01-09 Evidence Level: High Target Examinations: MRCPCH, FRACP, USMLE Step 2/3, PLAB